IDEMIA/TYMEBANK
9.12.2020 14:02:15 CET | Business Wire | Press release
TymeBank, South Africa’s first truly digital bank, teams up with IDEMIA, the global leader in Augmented Identity, to deliver a secure, convenient and frictionless way for customers to acquire bank cards.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201209005463/en/
Committed to expanding banking services to all South Africans, TymeBank proactively leverages innovative digital technology to deliver a safe and frictionless banking experience to its over 2.5 million customers. Working closely with IDEMIA, TymeBank continues to onboard approximately 120 000 customers per month and works tirelessly to ensure that a secure suite of banking services is continuously made available to its customers.
As the world leader in Augmented Identity, IDEMIA has a proud track record of providing a trusted environment enabling consumers to perform their daily banking activities. Leveraging biometric authentication and other innovative technology solutions, IDEMIA continues to deliver verified identities and secure transactions for people worldwide.
Leaders in their respective fields, both TymeBank and IDEMIA are working together to provide customers with dual interface chip cards (EMVi ) in a secure and convenient manner. In a survey this year, 75% of South Africans are turning to contactless payments citing hygiene reasons1 . The EMV card, which facilities secure transactions at Point-of-Sale (POS), also supports a safe and contactless payment experience for the consumer. This way of transacting is set to become more important with the upcoming holiday season, as an increasing number of consumers choose to do contactless payments. Since the onset of the Covid-19 pandemic, 89% of South African respondents in the same survey say they prefer using contactless payment options2 .
TymeBank debit cards are issued at self-service kiosks, which are stationed at Pick ’n Payii and Boxeriii stores around the country. A TymeBank customer can open an account and collect the bank card at their convenience after successfully verifying their identity with a valid South African ID number. The verification process is a key step towards fighting identity fraud, which since the start of the pandemic has resulted in an estimated cost to the South African economy of over R 1 billion3 .
“TymeBank has reached yet another key milestone, now that the bank has onboarded 2.5 million customers since our launch in February 2019, ,” said Cheslyn Jacobs, Head of Sales and Service at TymeBank. “Our customers value our offering as TymeBank makes banking simple and secure. Our partnership with IDEMIA is to the benefit of our customers. We equip our customers with a contactless EMV bank card that delivers a safe payment experience in a secure and convenient manner. This is true to our ethos of ensuring that banking is made accessible to everyone in South Africa.”
In addition to being an identity technology leader, IDEMIA is also a trusted partner of financial institutions, working with local banks to introduce innovative payment products, including the country’s first vertical metal card. With a full service, state-of-the-art card personalization center in Johannesburg, the biggest in South Africa, IDEMIA has been working closely with South African banks for over 10 years to ensure that bank cards are delivered securely and quickly to consumers, enabling them to fulfill everyday transaction needs.
“We are honored by the trust that TymeBank places in us and our solutions,” said Julia Schoonenberg, Senior Vice President (MEA), Financial Instiutions, IDEMIA. “As a global leader in secure payment technologies, IDEMIA has a proven track record of working with banking customers in both physical and digital spaces. We are proud to support TymeBank in their mission to enhance convenience and payment security for even more people in South Africa.”
-END-
About IDEMIA
IDEMIA, the global leader in Augmented Identity, provides a trusted environment enabling citizens and consumers alike to perform their daily critical activities (such as pay, connect and travel), in the physical as well as digital space.
Securing our identity has become mission critical in the world we live in today. By standing for Augmented Identity, an identity that ensures privacy and trust and guarantees secure, authenticated and verifiable transactions, we reinvent the way we think, produce, use and protect one of our greatest assets – our identity – whether for individuals or for objects, whenever and wherever security matters. We provide Augmented Identity for international clients from Financial, Telecom, Identity, Public Security and IoT sectors. With close to 15,000 employees around the world, IDEMIA serves clients in 180 countries.
For more information, visit www.idemia.com / Follow @IDEMIAGroup on Twitter
About TymeBank
TymeBank is South Africa’s first digital bank. It is majority owned by ARC Financial Services Holdings (Pty) Ltd, a company within Patrice Motsepe’s Ubuntu-Botho Investments stable. TymeBank has no branches and its core banking system is hosted securely in the Cloud. This reduces its overheads and delivers significant cost-savings that are passed on to its customers. Through a distribution partnership with Pick n Pay and Boxer, TymeBank has kiosks located at stores across the country. Customers can open a FICA compliant bank account at these kiosks in under five minutes. No documentation is required. Once signed-up customers can automatically become Smart Shopper members – Pick n Pay’s rewards programme – and will earn double Smart Shopper points when using their TymeBank card to purchase goods in Pick n Pay stores. TymeBank’s unique GoalSave tool, allows customers to earn a great interest rate of up to 8% per annum on their savings. For more information visit www.tymebank.co.za .
1
https://www.bizcommunity.com/Article/196/706/203659.html
2
https://www.bizcommunity.com/Article/196/706/203659.html
3
https://www.cbn.co.za/featured/identity-fraud-costs-sa-over-r1-billion-during-covid-19/
i
EMV — which stands for Europay, Mastercard and Visa — is a global standard for cards equipped with computer chips and the technology used to authenticate chip-card transactions. In the wake of numerous large-scale data breaches and increasing rates of counterfeit card fraud, U.S. card issuers have migrated to this new technology to protect consumers and reduce the costs of fraud. https://www.creditcards.com/credit-card-news/emv-faq-chip-cards-answers-1264/
ii
Pick n Pay - A retailer in South Africa, which began in 1967, it now has 1.500 stores in the country https://www.pnp.co.za/about-us/history
iii
Boxer – A chain of discount stores in South Africa which started in 1977, it now operates over 300 stores in South Africa. https://www.boxer.co.za/company-history/
View source version on businesswire.com: https://www.businesswire.com/news/home/20201209005463/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
